At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06998 EDDING GENOR
Closing Auction 03-20 16:08:04
2.640
+0.010
+0.38%
High2.720
Low2.610
Vol555.00K
Open2.690
D1 Closing2.630
Amplitude4.18%
Mkt Cap5.28B
Tradable Cap5.28B
Total Shares2.00B
T/O1.48M
T/O Rate0.03%
Tradable Shares2.00B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Edding Genor (06998) Sets 27 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend
Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in the biopharmaceuticals business. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241) and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its businesses in the domestic market.